Alison J Moskowitz, Gunjan Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Samia Sohail, Alayna Santarosa, Natasha Galasso, Rachel Neuman, Brielle Liotta, William Blouin, Anita Kumar, Oscar Lahoud, Connie L Batlevi, Paul Hamlin, David J Straus, Ildefonso Rodriguez-Rivera, Colette Owens, Philip Caron, Andrew M Intlekofer, Audrey Hamilton, Steven M Horwitz, Lorenzo Falchi, Erel Joffe, William Johnson, Christina Lee, M Lia Palomba, Ariela Noy, Matthew J Matasar, Georgios Pongas, Gilles Salles, Santosha Vardhana, Beatriz Wills Sanin, Gottfried von Keudell, Joachim Yahalom, Ahmet Dogan, Andrew D Zelenetz, Craig H Moskowitz
PURPOSE: We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550). METHODS: Transplant eligible patients with rel/ref cHL following first-line therapy were treated with two to four cycles of pembrolizumab (200 mg intravenous [IV], day 1), gemcitabine (1,000 mg/m2 IV, days 1 and 8), vinorelbine (20 mg/m2 IV, days 1 and 8), and liposomal doxorubicin (15 mg/m2 , days 1 and 8), given on 21-day cycles...
October 1, 2021: Journal of Clinical Oncology